KEFAMAST Dry Cow Intramammary Suspension

البلد: أيرلندا

اللغة: الإنجليزية

المصدر: HPRA (Health Products Regulatory Authority)

العنصر النشط:

Cefalexin; Dihydrostreptomycin sulfate

متاح من:

Bimeda Animal Health Limited

ATC رمز:

QJ51RD01

INN (الاسم الدولي):

Cefalexin; Dihydrostreptomycin sulfate

جرعة:

500/500 mg/syringe

الشكل الصيدلاني:

Intramammary suspension

نوع الوصفة الطبية :

POM: Prescription Only Medicine as defined in relevant national legislation

المجال العلاجي:

cefalexin, combinations with other antibacterials

الوضع إذن:

Authorised

تاريخ الترخيص:

1988-10-01

خصائص المنتج

1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
KEFAMAST Dry Cow Intramammary Suspension
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each syringe contains:
ACTIVE SUBSTANCES:
Cefalexin
500 mg
Dihydrostreptomycin
500 mg
(as Dihydrostreptomycin Sulphate)
EXCIPIENTS:
QUALITATIVE COMPOSITION OF EXCIPIENTS AND
OTHER CONSTITUENTS
Cera alba
Liquid paraffin
Smooth, pale pink or pale yellow suspension.
3.
CLINICAL INFORMATION
3.1
TARGET SPECIES
Cattle (dry cows).
3.2
INDICATIONS FOR USE FOR EACH TARGET SPECIES
For the treatment of sub clinical mastitis infection present at drying
off in cows and to assist in
preventing new infections occurring during the dry period.
3.3
CONTRAINDICATIONS
Do not use in cases of hypersensitivity to the active substances or to
any of the excipients.
Do not use in lactating cows.
Do not use within 40 days of the estimated calving date.
3.4
SPECIAL WARNINGS
None.
3.5
SPECIAL PRECAUTIONS FOR USE
Special precautions for safe use in the target species:
Use of the product should be based on identification and
susceptibility testing of the target
pathogen(s). If this is not possible, therapy should be based on
epidemiological information and
knowledge of susceptibility of the target pathogens at farm level, or
at local/regional level.
Use of the product should be in accordance with official, national and
regional antimicrobial policies.
An antibiotic with a lower risk of antimicrobial resistance selection
(lower AMEG category) should be
used for first line treatment where susceptibility testing suggests
the likely efficacy of this approach.
Narrow spectrum antibiotic therapy with a lower risk of antimicrobial
resistance selection should be
used for first line treatment where susceptibility testing suggests
the likely efficacy of this approach.
The feeding of waste milk containing residues of cefalexin to calves
should be avoided up to the end
of the milk withdrawal period (except during the colostral phase),
because it could select
antimicrobial-resistant bacteria within the intestinal microbiota of
th